Yale s Akiko Iwasaki, PhD, named to TIME100 Lists of Most Influential People in the World bubblear.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bubblear.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ TIME has named Yale School of Medicine immunobiologist Dr. Akiko Iwasaki to the 2024 TIME100 Health, the magazine s annual list of the 100 most.
Serimmune Launches COVID Antibody Epitope Mapping Service
Better understand the B-cell response to SARS-CoV-2 infection and vaccination with high-resolution antibody epitope mapping across the entire SARS-CoV-2 proteome
News provided by
Share this article
Share this article
GOLETA, Calif., March 11, 2021 /PRNewswire/ Serimmune Inc., a leader in understanding the functional antibody repertoire s role in human disease, today announced the launch of a COVID antibody epitope mapping discovery service. This offering now provides academic and biopharma researchers with ready access to Serimmune s proprietary Serum Epitope Repertoire Analysis (SERA) technology.
Requiring only 100 ul of serum or plasma per sample, Serimmune analyzes each sample for IgG and/or IgM antibodies using its proprietary, 10 billion member, random, bacterial peptide display library. In addition to providing a composite score of the antibody epitopes identified in each sample to those observed in cohorts o
76% Efficacy, Reduced Transmission Potential Shown by AstraZeneca/Oxford COVID-19 Vaccine
February 3, 2021
Data posted by researchers from the University of Oxford, AstraZeneca, and partners showed a single dose of their COVID-19 vaccine to be 76% effective from 22 to 90 days following vaccination, while a two-dose regimen proved more effective the longer the interval between doses. [University of Oxford]
Share
Data from four clinical trials posted today by researchers from the University of Oxford, AstraZeneca, and partners showed a single dose of their COVID-19 vaccine to be 76% effective from 22 to 90 days following vaccination, while a two-dose regimen proved more effective the longer the interval between doses.
January 28, 2021
HARLOW, UK: Now that many questions regarding COVID-19, including its symptoms, risks and recovery time, have been answered, researchers are faced with a new dilemma: SARS-CoV-2 reinfection and immunity. Although unusual, it is evident that reinfections do occur, and in a recent study, researchers explored whether individuals who have recovered from COVID-19 are protected from future infection. The findings suggested that past infection may provide natural immunity and that the said immunity is effective for approximately half a year after the initial infection.
In what is considered to be the largest study of SARS-CoV-2 reinfection, researchers in the UK recruited 6,614 healthcare workers. They received SARS-CoV-2 polymerase chain reaction and antibody testing every two to four weeks and completed questionnaires on their symptoms and exposures every two weeks. The researchers found that approximately 83% of the participants who had a prior history of SARS-CoV-2 in